New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 6, 2012
17:40 EDTAPRIApricus Biosciences CEO Bassam Damaj resigns, CFO Steve Martin named interim CEO
Apricus Biosciences announced that Bassam Damaj, Ph.D., has resigned as a director, president, and CEO of the company and that Steve Martin, senior vice president and CFO, has been appointed interim CEO. The changes are effective immediately. The company also announced that its board has retained an executive recruiting firm to assist in identifying a permanent CEO whose experience is expected to include significant background in commercial operations within the pharmaceutical industry.
News For APRI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 27, 2015
16:34 EDTAPRIApricus Biosciences announces issuance of U.S. patent for RayVa
Apricus Biosciences announced that , January 27, 2015, the United States Patent and Trademark Office, USPTO, issued to Apricus, U.S. Patent No. 8,940,794, titled "METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE," with claims generally directed to methods for treating Raynaud's phenomenon, that is secondary to systemic sclerosis. The patent is expected to expire no earlier than its twenty-year term in 2032. RayVa is the proprietary name for Apricus' product candidate for the treatment of Raynaud's phenomenon. Raynaud's phenomenon is a circulatory disorder affecting the hands and feet. Raynaud's phenomenon secondary to systemic sclerosis affects an estimated three to five percent of people in the U.S., disproportionately affecting women and currently has no approved therapy in the U.S., representing an unmet medical need. The FDA has indicated that Apricus' RayVa product may qualify for priority review, given the unmet medical need and lack of approved products to treat secondary Raynaud's phenomenon. The FDA will determine if the RayVa New Drug Application qualifies for priority review following its submission, which could occur as early as 2017.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use